Verrica Pharmaceuticals Inc.
Tremor tracks 5 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- VRCAVerrica Pharmaceuticals Inc.0Calm
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Running, no new patientsPhase 3302 patientsMain results: Nov 2026 - VRCAVerrica Pharmaceuticals Inc.0Calm
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Signing up patientsPhase 3250 patientsMain results: Nov 2027 - VRCAVerrica Pharmaceuticals Inc.0Calm
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
Not started yetPhase 230 patientsMain results: Apr 2027 - VRCAVerrica Pharmaceuticals Inc.0Calm
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)
Signing up patientsPhase 3300 patientsMain results: May 2027 - VRCAVerrica Pharmaceuticals Inc.0Calm
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
FinishedPhase 292 patientsMain results: Apr 15, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 6 purchases
- Rosenberg Noah L.CMO · Aug 18, 2026Bought 2,030 sharesabout $10 thousand ·
- Kirby John J.Interim CFO · Aug 18, 2026Bought 5,000 sharesabout $25 thousand ·
- Zawitz DavidChief Operating Officer · Aug 17, 2026Bought 6,000 sharesabout $30 thousand ·
- Rieger JaysonCEO and President · Aug 17, 2026Bought 5,000 sharesabout $25 thousand ·
- Rosenberg Noah L.CMO · Aug 17, 2026Bought 4,200 sharesabout $21 thousand ·
- Rieger JaysonCEO and President · Aug 14, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.